Jose Valdes PharmD
Travis Shipley
Jose A. Rey MS, PharmD, BCPP

Loxapine inhalation powder (Adasuve, Teva), approved by the FDA on December 21, 2012, utilizes an antipsychotic with more than three decades of experience in a novel delivery system for the treatment of agitation associated with schizophrenia or bipolar mania.

Krishna R. Patel PharmD, RPh
Jessica Cherian PharmD, RPh
Kunj Gohil PharmD, RPh

Schizophrenia is a complex, chronic mental health disorder characterized by an array of symptoms, including delusions, hallucinations, disorganized speech or behavior, and impaired cognitive ability. The early onset of the disease, along with its chronic course, make it a disabling disorder for many patients and their families. Disability often results from both negative symptoms (characterized by loss or deficits) and cognitive symptoms, such as impairments in attention, working memory, or executive function. In addition, relapse may occur because of positive symptoms, such as suspiciousness, delusions, and hallucinations. The inherent heterogeneity of schizophrenia has resulted in a lack of consensus regarding the disorder’s diagnostic criteria, etiology, and pathophysiology.

This article provides a concise review of schizophrenia and discusses the available treatment options.

Stephen Barlas

Sandoz’s announcement that the Food and Drug Administration (FDA) has accepted its application for approval of filgrastim as potentially the first biosimilar drug to be licensed in the U.S. set off one of the periodic fits of attention paid to the absence of biosimilars in the U.S. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was supposed to set off a run by companies seeking FDA approval of biosimilars they already sell in Europe and Asia. That law was passed as an amendment to the Affordable Care Act, which Congress approved in 2010.

James O’Donnell PharmD
F. Randy Vogenberg RPh, PhD

The problems of wrong-drug, wrong-dose, and other fundamental medication errors persist despite improvements in quality-review systems and technology. Clearly, gaps remain, and vigilance with regard to these issues is required in an era of tighter scrutiny of budgets and health care outcomes in the post-Affordable Care Act environment. The alternative is rapidly increasing litigation costs and loss of licensure and professional standing, not to mention the potential for greater oversight by regulatory bodies and the public.

Breaking News

If approved, product’s launch expected in second quarter, 2015
100% of patients respond to treatment within 24 hours
Treating inflammation may be bad idea, authors say
Electronic health records increase docs’ bureaucratic burden, authors say
Absence of single gene drives inflammation
Noninvasive method detects compounds produced by Aspergillus fungi
Capsules reduce exogenous insulin requirements in mid-stage trial

P&T TV

From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash

A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.

Interview

Meetings

Nashville, TN
November 3 to November 4
Brussels, Belgium
November 12 to November 14

P&T Past Issues

Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.